Top Page
Osteopore Ltd.
(Sydney:OSX)
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Osteopore Ltd. Business Overview & Revenue Model
Osteopore Ltd. Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.06M | 2.81M | 2.22M | 1.69M | 1.11M |
| Gross Profit | 1.62M | 2.37M | 1.64M | 1.27M | 811.64K |
| EBITDA | -1.92M | -2.34M | -4.35M | -3.97M | -3.38M |
| Net Income | -3.72M | -3.35M | -4.87M | -4.22M | -3.62M |
Balance Sheet | |||||
| Total Assets | 2.77M | 3.13M | 3.34M | 3.62M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 626.97K | 638.50K | 1.16M | 1.35M | 4.55M |
| Total Debt | 198.80K | 1.33M | 1.09M | 74.18K | 106.71K |
| Total Liabilities | 4.50M | 2.83M | 2.91M | 1.51M | 633.40K |
| Stockholders Equity | -1.73M | 306.22K | 432.60K | 2.11M | 5.37M |
Cash Flow | |||||
| Free Cash Flow | -2.57M | -3.10M | -3.74M | -4.06M | -4.00M |
| Operating Cash Flow | -2.56M | -3.09M | -3.74M | -4.00M | -3.81M |
| Investing Cash Flow | -10.79K | -14.59K | -7.37K | -63.98K | -194.62K |
| Financing Cash Flow | 2.67M | 2.63M | 3.58M | 896.32K | -485.88K |
Osteopore Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$21.89M | -4.71 | -27.84% | ― | 6.77% | -8.45% | |
56 Neutral | AU$210.74M | -127.08 | -2.01% | ― | 16.93% | 76.47% | |
52 Neutral | AU$94.16M | -11.14 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$41.13M | -6.22 | -81.30% | ― | -36.68% | 79.41% | |
43 Neutral | AU$3.86M | -0.50 | -487.52% | ― | 5.52% | 49.25% | |
41 Neutral | AU$244.18M | -17.68 | -89.70% | ― | 42.05% | -0.84% |
Osteopore Ltd. Corporate Events
Osteopore Limited reported record revenue of $3.06 million for the year ended 31 December 2025, an 11% increase driven by stronger traction across core markets and product segments. Despite this top-line growth, the company’s net loss after tax also widened by 11% to $3.72 million, as operating expenses rose due to higher product development, laboratory spending, and expanded compliance efforts.
The company’s net tangible assets per share deteriorated to negative 0.67 cents, reflecting balance sheet pressure as it invests for broader commercial deployment and regulatory readiness. Osteopore also incorporated a new wholly owned subsidiary, OsteoRx Pte Ltd in August 2025, underscoring its push toward long-term growth and scalable international operations, though no dividend was declared for the year.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has lodged an application with the ASX for quotation of 50,000,000 ordinary fully paid shares under code OSX, with an issue date of 11 February 2026. The move expands the company’s quoted share base, signalling a material change in its capital structure that may affect liquidity and ownership dynamics for existing and prospective shareholders.
The application, made under Appendix 2A of the ASX Listing Rules, reflects the conversion or issue of securities that are now being admitted to quotation on the exchange. This step formalises the listing of the new shares and positions Osteopore to access broader market participation through the enlarged pool of tradable securities.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has launched a state-of-the-art 3D printing services line in Singapore, offering pre-surgical planning models and sterilised intra-operative cutting jigs to both public and private hospitals. The move, driven by direct demand from hospitals and surgeons, enables the company to extend beyond implants into digital surgical planning, customised design and additive manufacturing.
By expanding its role along the surgical value chain, Osteopore aims to improve surgical precision, reduce lead times and optimise hospital resource use, while diversifying and increasing higher-value revenue streams. The initiative positions the company to capitalise on the rapidly growing global healthcare 3D printing market, forecast to quadruple to more than USD 8 billion by the early 2030s, with Asia-Pacific expected to be one of the fastest-growing regions.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has notified the market of the issue of additional unquoted convertible notes, identified under ASX code OSXAM, as part of its capital structure on 6 February 2026. The relatively small issuance of 10 convertible notes signals a targeted funding or structural adjustment move rather than a large capital raise, indicating incremental balance-sheet activity that existing stakeholders may monitor for its impact on future equity dilution and financing flexibility.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has completed the final A$500,000 drawdown of Tranche 1 of its 4.0% redeemable convertible notes under a subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I, bringing the total nominal amount issued under the first A$5 million tranche to A$5 million across 20 sub‑tranches. The fresh capital will be deployed to support Osteopore’s ordinary operations and fund future developments, projects and investments as opportunities arise, bolstering the company’s financial flexibility as it pursues growth in regenerative medicine and 3D‑printed implant markets.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has applied to the Australian Securities Exchange for quotation of 70 million new fully paid ordinary shares, to be traded under its existing ticker, OSX, from 3 February 2026. The sizeable securities issuance signals a significant capital move that could broaden the company’s shareholder base and provide additional funding capacity, with potential implications for existing investors through dilution and for the company’s ability to finance future operational or strategic initiatives.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore has entered a partnership with the Tam Shiu Anatomical Modelling Laboratory at the University of Hong Kong to advance digital design and workflows for anatomical models, surgical guides, cutting jigs and the digital reconstruction of bone gaps and augmentation sites across the body. As part of the collaboration, the company will establish its second Global Centre of Excellence in Hong Kong — its first outside Singapore — a move aimed at deepening engagement with surgeons, integrating more closely with the hospital ecosystem, and strengthening its operational and clinical footprint in a key Asian medical hub.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Ltd has applied to the ASX for quotation of 20 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The share issuance, dated 27 January 2026, will expand the company’s quoted capital base, potentially improving trading liquidity and providing additional funding capacity, with implications for existing shareholders through capital structure and possible dilution effects.
The most recent analyst rating on (AU:OSX) stock is a Buy with a A$0.02 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has clarified details of its exclusive agreement with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic implant products into Hong Kong. While Hong Kong itself is not considered a major bone trauma market, Osteopore emphasises the territory’s strategic role as a regulatory and market gateway into China’s Guangdong-Hong Kong-Macao Greater Bay Area, a region of over 87 million people and RMB 14.5 trillion GDP, positioning the deal as a significant long-term opportunity despite the current inability to quantify its potential economic impact; the agreement is described as containing standard market terms with no additional material conditions or minimum performance criteria.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed an exclusive three-year distribution agreement, with an option for a one-year extension, with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic products into Hong Kong, initially targeting the orthopaedic trauma reconstruction market where its devices have the strongest application potential. While Hong Kong is a relatively small market, Osteopore’s move positions the company in a strategically important hub to access the Greater Bay Area and benefit from emerging regulatory harmonisation for medical devices across China’s regional healthcare network, aligning the business with a fast-growing Asia-Pacific bone graft and substitutes market projected to expand at an 8.2% CAGR through 2030.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has applied to the ASX for quotation of 10 million new fully paid ordinary shares, with the securities to be issued and quoted on 20 January 2026 under the ticker OSX. The move expands the company’s listed share base and may provide additional capital flexibility and liquidity for existing and new investors, although the announcement does not disclose the purpose of the issuance or associated funding details.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has applied to the Australian Securities Exchange for quotation of 50 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The securities were issued on 16 January 2026, signaling a significant expansion of the company’s listed share base that may affect its capital structure and liquidity profile, with implications for existing shareholders as the enlarged register comes to market.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has entered an exclusive commercialisation agreement with Majeton to distribute its dental, orthodontic and maxillofacial regenerative implants across China, Hong Kong and Macau, marking a strategic move to penetrate the Greater China market. The deal, effective from 15 January 2026, includes staged payments tied to regulatory and sales milestones, such as upfront dossier fees, payments on regulatory approvals in Macau and China, and volume-based bonuses for units sold in the Greater Bay Area and mainland China, signalling a structured pathway to revenue growth and broader regional adoption of Osteopore’s technology.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed a multi-year, exclusive distribution agreement worth more than RMB 12 million with Majeton Pte Ltd to commercialise its dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The deal, which includes upfront and milestone payments tied to sales and regulatory achievements, gives Osteopore access to the Chinese dental bone graft substitute and membrane market via Majeton and its parent Essex Bio-Technology Limited, whose extensive hospital network and sales infrastructure are expected to accelerate Osteopore’s regional expansion and reinforce its strategy of leveraging established partners to scale commercialisation and improve patient outcomes.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has notified the market of the issue of five unquoted convertible notes under the security code OSXAM, with the issue dated 14 January 2026. The small-scale issuance of these convertible notes indicates the company is continuing to use structured, non-listed securities as part of its capital management strategy, which may provide additional funding flexibility without immediate dilution for ordinary shareholders.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has issued a cleansing notice in connection with a new $250,000 sub‑tranche (ST18 of T1) of redeemable convertible notes subscribed for by Advance Opportunities Fund and Advance Opportunities Fund I under an existing subscription agreement of up to $20 million. The notice confirms that these Sixth Convertible Notes will be issued without a prospectus, and that ordinary shares issued upon their conversion can be freely on‑sold to retail investors, reflecting the company’s continued use of staged convertible note funding to support its capital needs while maintaining compliance with Australian corporate and ASX disclosure requirements.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has drawn a further A$250,000 sub-tranche (ST18) from Tranche 1 of its 4.0% redeemable convertible notes facility with Advance Opportunities Fund and Advance Opportunities Fund I, taking total subscriptions under Tranche 1 to A$4.5 million out of a planned A$5 million. The funds raised under the up-to-A$20 million multi-tranche notes program are earmarked for use in the ordinary course of business and to support future developments, projects and investments as opportunities arise, bolstering Osteopore’s capital position as it seeks to expand its regenerative implant operations and pursue growth initiatives.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed an exclusive 15-year licensing agreement with Accelerate Technologies, the commercialisation arm of Singapore’s A*STAR, to use a Heparan Sulphate bioactive technology platform designed to significantly accelerate bone and tissue regeneration when combined with Osteopore’s existing implant technology. The licence, which includes patents and know-how for two Heparan Sulphate families such as HS3 and covers all life science, medical, research and clinical uses across key global markets, positions Osteopore to access the fast-growing bone morphogenetic protein-2 (BMP-2) market in Asia-Pacific, valued at USD 670 million in 2024 and forecast to expand at 8.5% annually, although the company does not expect a short-term material impact on earnings as clinical trials and regulatory milestones progress.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Advance Opportunities Fund I has lodged a notice under Australia’s Corporations Act stating it has ceased to be a substantial shareholder in Osteopore Limited. The filing, dated 30 December 2025, indicates that the fund’s relevant interest in Osteopore’s voting securities has fallen below the substantial holding threshold, signalling a change in the company’s share register that may alter its investor base and potentially affect perceptions of institutional support.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Ltd. has announced the quotation of 16,949,152 new fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 11, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and potentially expand its market presence, which could have significant implications for its growth and stakeholder value.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.